Mascoma Wealth Management LLC Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Mascoma Wealth Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.3% in the 4th quarter, HoldingsChannel reports. The firm owned 1,641 shares of the company’s stock after acquiring an additional 111 shares during the quarter. Mascoma Wealth Management LLC’s holdings in Johnson & Johnson were worth $237,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. raised its position in Johnson & Johnson by 557.1% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 375,834 shares of the company’s stock worth $54,353,000 after acquiring an additional 318,642 shares during the period. Rakuten Securities Inc. increased its stake in shares of Johnson & Johnson by 64.6% during the 4th quarter. Rakuten Securities Inc. now owns 1,149 shares of the company’s stock worth $166,000 after purchasing an additional 451 shares during the last quarter. Essential Planning LLC. bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $3,252,000. Jupiter Asset Management Ltd. lifted its stake in Johnson & Johnson by 10,455.7% in the fourth quarter. Jupiter Asset Management Ltd. now owns 144,402 shares of the company’s stock valued at $20,883,000 after purchasing an additional 143,034 shares during the last quarter. Finally, Liberty Wealth Management LLC grew its holdings in Johnson & Johnson by 10.4% during the fourth quarter. Liberty Wealth Management LLC now owns 3,543 shares of the company’s stock valued at $512,000 after purchasing an additional 333 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

JNJ stock opened at $162.93 on Thursday. The firm has a 50 day simple moving average of $154.23 and a two-hundred day simple moving average of $156.34. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market cap of $392.27 billion, a PE ratio of 24.50, a P/E/G ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the prior year, the firm earned $2.29 earnings per share. The firm’s revenue was up 5.3% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.04%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analysts Set New Price Targets

JNJ has been the topic of a number of research reports. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday. Raymond James lowered their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Leerink Partners lowered their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Finally, Wells Fargo & Company cut their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.